ELI LILLY AND COMPANY Impairment of Intangible Assets, Finite-lived
ELI LILLY AND COMPANY (LLY) reported Impairment of Intangible Assets, Finite-lived of $128.00 million for the 12-month period ending 2021-12-31, per its 10-K filed 2024-02-21.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2024-02-21
- ELI LILLY AND COMPANY impairment of intangible assets, finite-lived for fiscal 2021 was $128.00M.
- ELI LILLY AND COMPANY impairment of intangible assets, finite-lived for fiscal 2015 was $0.00.
- ELI LILLY AND COMPANY impairment of intangible assets, finite-lived for fiscal 2014 was $0.00.
- ELI LILLY AND COMPANY impairment of intangible assets, finite-lived for fiscal 2013 was $0.00.
| Period end | Impairment of Intangible Assets, Finite-lived 12 month | Impairment of Intangible Assets, Finite-lived 36 month |
|---|---|---|
| 2021-12-31 | $128.00M 10-K · filed 2024-02-21 | |
| 2018-12-31 | $46.90M 8-K · filed 2019-10-24 | |
| 2015-12-31 | $0.00 10-K · filed 2016-02-19 | |
| 2014-12-31 | $0.00 10-K · filed 2015-02-19 | |
| 2013-12-31 | $0.00 10-K · filed 2014-02-19 | |
| 2012-12-31 | $0.00 10-K · filed 2014-02-19 | $0.00 10-K · filed 2013-02-21 |
| 2011-12-31 | $0.00 10-K · filed 2014-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |